您的当前位置:首页 > 行业数据 > 2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导
图片属性
图片格式:PNG 图片大小:67KB 图片尺寸:1594*810
同报告图片
 / 4
2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导_第1页
fCDlubTku70gfCDooYDmtrLpgI/mnpDvvIjkurrvvIkgfCDohbnohpzpgI/mnpDvvIjkurrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwKfCAyMDExIHwgMjUwMDAwICAgICAgICAgfCA1MDAwMCAgICAgICAgICB8CnwgMjAxMiB8IDI4MDAwMCAgICAgICAgIHwgMzAwMDAgICAgICAgICAgfAp8IDIwMTMgfCAzMjAwMDAgICAgICAgICB8IDQwMDAwICAgICAgICAgIHwKfCAyMDE0IHwgMzgwMDAwICAgICAgICAgfCA1MDAwMCAgICAgICAgICB8CnwgMjAxNSB8IDQyMDAwMCAgICAgICAgIHwgNjAwMDAgICAgICAgICAgfAp8IDIwMTYgfCA0ODAwMDAgICAgICAgICB8IDcwMDAwICAgICAgICAgIHwKfCAyMDE3IHwgNTUwMDAwICAgICAgICAgfCA4MDAwMCAgICAgICAgICB8CnwgMjAxOCB8IDYyMDAwMCAgICAgICAgIHwgOTAwMDAgICAgICAgICAgfAp8IDIwMTkgfCA2ODAwMDAgICAgICAgICB8IDEwMDAwMCAgICAgICAgIHwKfCAyMDIwIHwgNzUwMDAwICAgICAgICAgfCAxMTAwMDAgICAgICAgICB8CnwgMjAyMSB8IDgyMDAwMCAgICAgICAgIHwgMTIwMDAwICAgICAgICAgfAp8IDIwMjIgfCA5MDAwMDAgICAgICAgICB8IDEzMDAwMCAgICAgICAgIHwKfCAyMDIzIHwgOTgwMDAwICAgICAgICAgfCAxNDAwMDAgICAgICAgICB8CnwgMjAyNCB8IDEwNTAwMDAgICAgICAgIHwgMTUwMDAwICAgICAgICAgfAp8IDIwMjUgfCAxMTM3OTYyICAgICAgICB8IDE2MjI2MCAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muS4reWNjuWMu+WtpuS8muiCvuiEj+eXheWtpuWIhuS8mu+8jOWFieWkp+ivgeWIuOeglOeptuaJgA==
2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导_第2页
2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导_第3页
2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导_第4页
2025年在透患者130万例(血透113.7万、腹透16.2万),血透仍为主导_第5页
所属报告: 康臣药业-1681.HK-港股公司投资价值分析报告:多元并进肾科龙头高股息低估值弹性可期-260702(32页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠